33
Comment on the article “Morphodynamic classification of sandy beaches in low energetic marine environment” by Gómez-Pujol, L., Orfila, A., Cañellas, B., Alvarez-Ellacuria, A., Méndez, F.J., Medina, R. and Tintoré, J. Marine Geology, 242, pp. 235–246, 2007
92
Comment on the paper of de Ignacio, C., Muñoz, M., Sagredo, J., Fernández-Santín, S. and Johansson, A., 2006. Isotope geochemistry and FOZO mantle component of the alkaline–carbonatitic association of Fuerteventura, Canary Islands, Spain. Chem. Geol. 232,
180
Comment on: ‘A late Pleistocene clockwise rotation phase of Zakynthos (Greece) and implications for the evolution of the western Aegean Arc’: By Duermeijer, C.E., Krijgsman, W., Langereis, C.G., Meulenkamp, J.E., Triantaphyllou, M.V., Zachariasse, W.J., E
210
Comment on: “Cobeñas, G., Thouret, J.-C., Bonadonna, C., Boivin, P., 2012. The c.2030 yr BP Plinian eruption of El Misti volcano, Peru: Eruption dynamics and hazard implications. Journal of Volcanology and Geothermal Research 241-242, 105-120.”
321
Comment on: Geochemical and isotopic (Sr, U) variations of lake waters in the Ol’khon Region, Siberia, Russia: Origin and paleoenvironmental implications by F. Chabaux, M. Granet, P. Larqué, J. Riotte, E.V. Skliarov, O. Skliarova, L. Alexeieva, F. Risache
335
Comment on: Orbital cyclostratigraphy of the Devonian Frasnian–Famennian transition in South China, by Gong, Y.M., Li, B.H., Wang, Y., Wu, Y., Palaeogeogr. Palaeoclimatol. Palaeoecol. 168 (2001), 237–248
513
Commentary on “70 Gy vs. 80 Gy in localized prostate cancer: 5-Year results of GETUG 06 randomized trial.” Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissa
514
Commentary on “A comparison of outcomes for interfascial and intrafascial nerve-sparing radical prostatectomy”: Stolzenburg JU, Kallidonis P, Do M, Dietel A, Häfner T, Rabenalt R, Sakellaropoulos G, Ganzer R, Paasch U, Horn LC, Liatsikos E, Department of
519
Commentary on “A non-cancer-related survival benefit is associated with partial nephrectomy.” Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI, Cancer Prognostics and Health Outcomes
527
Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijv
528
Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijv
530
Commentary on “Adverse prognostic factors for testicular cancer-specific survival: A population-based study of 27,948 patients.” Fosså SD, Cvancarova M, Chen L, Allan AL, Oldenburg J, Peterson DR, Travis LB, Oslo University Hospital, University of Oslo, N
535
Commentary on “Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial.” Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakow
536
Commentary on “Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial.” Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakow
546
Commentary on “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.” Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan
547
Commentary on “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.” Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan
550
Commentary on “Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer.” Szarvas T, Jäger T, Laszlo V, Kramer G, Klingler HC, vom Dorp F, Romics I, Ergün S, Rübben H, Department of Urology, University of Duisburg-E
552
Commentary on “Common Genetic Polymorphisms Modify the Effect of Smoking on Absolute Risk of Bladder Cancer.” Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, Purdue MP, Sharma S, Fu
555
Commentary on “Comparative effectiveness of cryotherapy vs. brachytherapy for localized prostate cancer.” Williams SB, Lei Y, Nguyen PL, Gu X, Lipsitz SR, Yu HY, Kowalczyk KJ, Hu JC, Division of Urologic Surgery, Department of Radiation Oncology, Center f
569
Commentary on “Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians.” Berger J, Fardoun T, Brassart E, Capon G, Bigot P, Bernhard JC, Rigaud J, Patard JJ, Descazeaud A, Department of Urology, Dupuytren University
570
Commentary on “Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians.” Berger J, Fardoun T, Brassart E, Capon G, Bigot P, Bernhard JC, Rigaud J, Patard JJ, Descazeaud A, Department of Urology, Dupuytren University
576
Commentary on “Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy.” Wu K, Liu JJ, Adams W, Sonn GA, Mach KE, Pan Y, Beck AH, Jensen KC, Liao JC, Department of Urology, Stanford Cancer Center, Stanford University School o
581
Commentary on “Effects of prostate-specific antigen testing on familial prostate cancer risk estimates”: Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P, Department of Urology, Helsingborg Hospital, Helsingborg, Sweden. J Nat
583
Commentary on “ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.” Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC,
589
Commentary on “Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival”. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher
590
Commentary on “Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.” Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH, Division of Urology, Department o
602
Commentary on “Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.” Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S,
604
Commentary on “Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy.” Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salom
605
Commentary on “Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy.” Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salom
606
Commentary on “Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death”. Choueiri TK, Chen MH, DʹAmico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul
611
Commentary on “Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.” Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger
612
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,
613
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,
614
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,
624
Commentary on “Locally advanced prostate cancer: A population-based study of treatment patterns”. W.T. Lowrance, E.B. Elkin, D.S. Yee, A. Feifer, B. Ehdaie, L.M. Jacks, C.L. Atoria, M.J. Zelefsky, H.I. Scher, P.T. Scardino, J.A. Eastham, Department of Sur
627
Commentary on “Management of rectal injury during robotic radical prostatectomy.” Kheterpal E, Bhandari A, Siddiqui S, Pokala N, Peabody J, Menon M, Vattikuti Urology Institute, Henry Ford Health System, Henry Ford Hospital, Detroit, Michigan: Urology 201
632
Commentary on “Mortality results from the Göteborg randomized population-based prostate-cancer screening trial”: Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H, Department of Urology, Institute of
634
Commentary on “Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study”. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA, Department of Genitourinary M
642
Commentary on “Outcomes of robotic partial nephrectomy for renal masses with nephrometry score of ≥7.” White MA, Haber GP, Autorino R, Khanna R, Hernandez AV, Forest S, Yang B, Altunrende F, Stein RJ, Kaouk JH, Department of Surgery, Center for Laparoscop
643
Commentary on “Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.” Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL, Optimum Therapeutics, L.L.C., Columbus, OH: J U
647
Commentary on “Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.” Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shiple
652
Commentary on “Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.” Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania,
653
Commentary on “Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.” Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania,
654
Commentary on “Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75.” Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Wad
661
Commentary on “Predicting metastasized seminoma using gene expression.” Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, Meineke V, Abend M, Department of Urology, Federal Armed Forces Hospital, Hamburg, Germany : BJU Int 2012;110:E14
662
Commentary on “Predicting metastasized seminoma using gene expression.” Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, Meineke V, Abend M, Department of Urology, Federal Armed Forces Hospital, Hamburg, Germany : BJU Int 2012;110:E14
669
Commentary on “Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy”: Hong SK, Park HZ, Lee WK, Kim DS, Lee JS, Doo SH, Jeong SJ, Yoon CY, Byun SS, Lee SE, Department of Urology, Seoul National
671
Commentary on “Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up”. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs
678
Commentary on “Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients.” Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, K
679
Commentary on “Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients.” Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, K
682
Commentary on “Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010.” Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd, Hofmann JN, Chow WH, Purdue MP, Occupational and Environmental Epidemiology Branch, D
687
Commentary on “Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.” Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Cl
688
Commentary on “Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.” Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Cl
699
Commentary on “Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.” Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML,
700
Commentary on “Sipuleucel-T immunotherapy for castration-resistant prostate cancer”. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigator
702
Commentary on “Smoking negatively affects renal cell carcinoma overall and cancer-specific survival.” Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ, Institute of Urologic Oncology, D
716
Commentary on “Testicular cancer survivorship: Research strategies and recommendations”. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer
720
Commentary on “The clinical epidemiology of urachal carcinoma: Results of a large, population based study.” Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht,
721
Commentary on “The clinical epidemiology of urachal carcinoma: Results of a large, population based study.” Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht,
748
Commentary on “Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.” Choueiri TK, Lim ZD, Hirsch, MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, He
763
Commentary on Bevacizumab plus interferonα compared with interferonα monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206: Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutch
771
Commentary on Circulating microRNAs as stable blood-based markers for cancer detection: Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, OʹBriant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen, Stire
777
Commentary on Cumulative association of five genetic variants with prostate cancer: Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bنlter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL
794
Commentary on Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomized phase III trial: Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklu
795
Commentary on Essential roles of PI(3)K-p110β in cell growth, metabolism, and tumorigenesis: Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Bos
803
Commentary on Flexible robotic retrograde renoscopy: Description of novel robotic device and preliminary laboratory experience: Desai MM, Aron M, Gill IS, Pascal-Haber G, Ukimura O, Kaouk JH, Stahler G, Barbagli F, Carlson C, Moll F, Section of Laparoscop
805
Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer: Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kuma
808
Commentary on High-intensity focused ultrasound for prostate cancer: Comparative definitions of biochemical failure: Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, W
825
Commentary on Laboratory evaluation of laparoscopic vascular clamps using a load-cell device—are all clamps the same?: Lee HJ, Box GN, Abraham JB, Elchico ER, Panah RA, Taylor MB, Moskowitz R, Deane LA, McDougall EM, Clayman RV, Department of Urology, Uni
826
Commentary on Lack of comprehension of common prostate cancer terms in an underserved population: Kilbridge KL, Fraser G, Krahn M, Nelson EM, Conaway M, Bashore R, Wolf A, Barry MJ, Gong DA, Nease RF Jr., Connors AF, Massachusetts General Hospital, Genera
840
Commentary on Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis: Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, Gottesman MM, Wu Y, Yin JJ, Jia L, Chin
844
Commentary on Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer: Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Riga
858
Commentary on Pelvic Lymph Node Dissection in Prostate Cancer: Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE, Department of Urology, Vita-Salute University, Milan, Italy
861
Commentary on Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer: Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI, Genitourinary
869
Commentary on Prostate cancer severity among low income, uninsured men: Miller DC, Litwin MS, Bergman J, Stepanian S, Connor SE, Kwan L, Aronson WJ, Department of Urology, University of California, Los Angeles, CA
875
Commentary on Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis: Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT, Department of Uro
879
Commentary on Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial: Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schِffski P, Mainwarin
882
Commentary on Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer: Attard G, Reid AH, AʹHern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D
888
Commentary on Specific reduction of Fas-associated protein with death domain (FADD) in clear cell renal cell carcinoma: Xu H, He L, Feng X, Kapoor A, Tang D, Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China
892
Commentary on Surgery for metastatic urothelial carcinoma with curative intent: The German experience (AUO AB 30/05): Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Gr
893
Commentary on Surgical resection of renal cell carcinoma after targeted therapy: Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC, Glickman Urological and Kidney Institute, Clevela
894
Commentary on Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy: Nguyen CT, Lane BR, Kaouk JH, Hegarty N, Gill IS, Novick AC, Campbell SC, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, O
898
Commentary on Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model: Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen
901
Commentary on Testis-sparing surgery versus radical orchiectomy in patients with Leydig cell tumors: Loeser A, Vergho DC, Katzenberger T, Brix D, Kocot A, Spahn M, Gerharz EW, Riedmiller H, Department of Urology, Institute of Pathology, Julius-Maximilians
932
Commentary on Transcriptome sequencing to detect gene fusions in cancer: Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM, Michigan Center for Translational Pathology, Ann Arbor, MI
933
Commentary on Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma: Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, Tostain J, Guille F, Cindolo L, De La Taille A, Abbou CC, Salo
935
Commentary on Use of high fidelity operating room simulation to assess and teach communication, teamwork, and laparoscopic skills: Initial experience: Gettman MT, Pereira CW, Lipsky K, Wilson T, Arnold JJ, Leibovich BC, Karnes RJ, Dong Y, Departments of U
937
Commentary on Variation in KLK genes, prostate-specific antigen and risk of prostate cancer: Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, Albanes D, Giovannucci E, Stampfer MJ, Virtamo J, Thun MJ, Feigelson HS, Cancel-Tassin G, Cussenot O,
942
Commentary on: “Blood transfusions in radical prostatectomy: A contemporary population-based analysis”. J. Schmitges, M. Sun, F. Abdollah, Q.D. Trinh, C. Jeldres, L. Budäus, M. Bianchi, J. Hansen, T. Schlomm, P. Perrotte, M. Graefen, P.I. Karakiewicz, Mar
944
Commentary on: “Long-term functional outcomes after treatment for localized prostate cancer.” Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologi